Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Siemens, takes on Prowess DAO tech

This article was originally published in Clinica

Executive Summary

Siemens Healthcare has teamed up with radiotherapy company Prowess in a bid to develop new radiation oncology treatment planning software. The exclusive partnership will see Siemens integrate into its linear accelerators Prowess' direct aperture optimisation (DAO) technology. The DAO technology allows clinicians to make on-line corrections to the treatment plan based on pre-treatment CT scans, just before the patient is about to receive therapy. This combination is designed to help users reduce the amount of equipment in the workplace and cut down overall treatment times. Chico, California-based Prowess is currently developing the DAO-based Plan-to-Patient software for radiation therapy, which is undergoing clinical assessment and is scheduled to become commercially available in Q2 2008. According to Siemens, the Plan-to-Patient device works in conjunction with its CTVision system, an image-guided radiation therapy device.

You may also be interested in...



Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel